bioRxiv Science⌕ Search

Biology subjects

Ballesteros-Cuartero, P.

Publications and source records attributed to Ballesteros-Cuartero, P..

2 recordsLinked to original sources

Label Noise Limits TCR-pMHC Specificity Prediction: Improved Performance Through AlphaFold3-Based Structural Modeling and Data Denoising

T cell receptor (TCR) binding to peptides presented by major histocompatibility complex (MHC) molecules is a key step in T cell activation, and forms the basis of adaptive immunity. Predicting this specificity is therefore essential to developing effective TCR-based immunotherapies and vaccines. Despite its clinical relevance, predicting TCR-pMHC specificity for previously unseen peptides remains an open problem, with structural modeling so far the only strategy showing any predictive power in this setting. In this study, we find that this limited performance is substantially driven by label noise in the data used to train and evaluate these methods, an effect that has so far been largely underexplored. Using an AlphaFold3-based pipeline adapted for TCR-pMHC structural modeling, we achieve state-of-the-art specificity prediction, outperforming AlphaFold2.3-based and sequence based methods, and performing at par with the leading Immrep2025 competition submission. Combining this pipeline with a cluster-based denoising algorithm, we show that removing mislabeled points from a large specificity dataset increased binder ranking accuracy by more than 70% relative to the full dataset. Together, these results highlight label noise as a major factor limiting the performance that any method in this field can achieve, and show that combining structural modeling with label denoising substantially improves TCR-pMHC specificity prediction, making such approaches an attractive complement to current sequence-based approaches for refining TCR target selection.

bioinformatics↗

Unraveling the Power of NAP-CNB's Machine Learning-enhanced Tumor Neoantigen Prediction

In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNAseq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in vivo following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA-identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies

immunology↗